Drug Profile
Research programme: somatostatin receptor agonist therapeutics - Crinetics Pharmaceuticals
Alternative Names: CRN02481Latest Information Update: 13 May 2020
Price :
$50
*
At a glance
- Originator Crinetics Pharmaceuticals
- Class Antihypoglycaemics; Small molecules
- Mechanism of Action Somatostatin receptor 5 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hyperinsulinaemia
Most Recent Events
- 13 May 2020 9292080 - Info already covered
- 09 Mar 2020 Preclinical trials in Hyperinsulinaemia in USA (PO) before March 2020
- 05 Aug 2019 Crinetics Pharmaceuticals receives SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institutes of Health (NIH) for CRN 02481 development in Hyperinsulinaemia